Cutaneous desmop astic melanoma - Reappraisal of morphologic heterogeneity and prognostic factors

被引:150
作者
Busam, KJ
Mujumdar, U
Hummer, AJ
Nobrega, J
Hawkins, WG
Coit, DG
Brady, MS
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
关键词
desmoplastic; melanoma; prognostic factors;
D O I
10.1097/01.pas.0000141391.91677.a4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Desmoplastic melanoma (DM) is a variant of melanoma, which may be confused with nonmelanocytic benign or malignant spindle cell proliferations. The histologic hallmark of DM is the presence of fusiform melanocytes dispersed in a prominent collagenous stroma. Phenotypic heterogeneity of DM is underrecognized. Desmoplasia may be prominent throughout the entire tumor ("pure" DM) or represent a portion of an otherwise nondesmoplastic melanoma ("combined" DM). We reviewed melanomas with desmoplasia from 92 patients seen at a single institution between 1980 and 2002. Fifty-five of the tumors were pure DM. Thirty-seven were classified as combined. Mean follow-up of patients was 46 months for those alive at the last follow-up. Univariate analysis of clinical and pathologic parameters revealed four significant variables for disease-free survival: Clark level (IV vs. V; P = 0.005), DM subtype (pure vs. combined; P = 0.01), tumor mitotic rate (<1, 1-4, >4 mitoses/mm(2); P = 0.01), and tumor thickness (<1 mm, 1-4 mm, >4 mm; P = 0.02). Only histologic subtype (P = 0.02) and Clark level (P = 0.05) were independently significant by Cox regression analysis. Our results indicate that distinguishing pure from combined forms of DM is clinically relevant for prognosis (pure forms being associated with longer disease-specific survival). Failure to make this distinction may account for conflicting reports in the literature on the biologic behavior and prognosis of DM.
引用
收藏
页码:1518 / 1525
页数:8
相关论文
共 35 条
  • [1] DESMOPLASTIC MALIGNANT-MELANOMA - A CLINICOPATHOLOGICAL STUDY OF 25 CASES
    ANSTEY, A
    MCKEE, P
    JONES, EW
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (04) : 359 - 371
  • [2] Arbiser ZK, 2001, AM J CLIN PATHOL, V116, P473
  • [3] BAER SC, 1995, CANCER, V76, P2242, DOI 10.1002/1097-0142(19951201)76:11<2242::AID-CNCR2820761110>3.0.CO
  • [4] 2-I
  • [5] Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
    Balch, CM
    Buzaid, AC
    Soong, SJ
    Atkins, MB
    Cascinelli, N
    Coit, DG
    Fleming, ID
    Gershenwald, JE
    Houghton, A
    Kirkwood, JM
    McMasters, KM
    Mihm, MF
    Morton, DL
    Reintgen, DS
    Ross, MI
    Sober, A
    Thompson, JA
    Thompson, JF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3635 - 3648
  • [6] BEENKEN S, 1989, ARCH OTOLARYNGOL, V115, P374
  • [7] Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma
    Busam, KJ
    Iversen, K
    Coplan, KC
    Jungbluth, AA
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (02) : 197 - 204
  • [8] CARLSON JA, 1995, CANCER, V75, P478, DOI 10.1002/1097-0142(19950115)75:2<478::AID-CNCR2820750211>3.0.CO
  • [9] 2-O
  • [10] CONLEY J, 1971, CANCER, V28, P914, DOI 10.1002/1097-0142(1971)28:4<914::AID-CNCR2820280415>3.0.CO